Journal of Shandong University (Health Sciences) ›› 2024, Vol. 62 ›› Issue (3): 47-53.doi: 10.6040/j.issn.1671-7554.0.2024.0090

• Clinical Medicine • Previous Articles     Next Articles

Mining and analyzing cardiovascular adverse event signals for nintedanib based on the FDA Adverse Event Reporting System(FAERS)database

GAO Wen1, ZHANG Ge2, WEI Lai3, SU Lin2   

  1. 1.Department of Cardiology, The Fourth Peoples Hospital of Jinan, Jinan 250031, Shandong, China;
    2. Department of Respiratory and Critical Care, The Fourth Peoples Hospital of Jinan, Jinan 250031, Shandong, China;
    3. School of Law, Nanchang University, Nanchang 330031, Jiangxi, China
  • Published:2024-05-06

PDF (PC)

1132

Abstract: Objective To analyze the adverse reaction signals of nintedanib using the food and drug administration adverse event reporting system(FAERS)database. Methods Cases reported in the FAERS database from the July of 2014 to September of 2023 with nintedanib as suspected cause of adverse drug events were collected. After standardization of the WHO adverse drug reaction terminology, the reporting odds ratio method(ROR), proportional reporting ratio method(PRR)and multinomial gamma Posson distribution(MGPS)methods were used for adverse reaction signal detection. Results In total, 17,547 adverse reaction case reports listing nintedanib as the primary suspected drug were extracted from the FAERS database. Most patients were male(9,709 cases, 55.3%). The age mainly ranged from 65 to 85(8,856 cases, 50.5%). The majority of cases were reported from United States(10,209 cases, 58.2%), and the largest number of cases was reported in 2022(2,876 cases, 17.46%). In total, 24 cardiovascular adverse reaction signals were obtained through the ROR, PRR and MGPS methods, among which the RORs were highest for paroxysmal arrhythmia, aortic rupture, aortic valve calcification, heart valve surgery, and cardiac catheterization were ranked higher. The reported adverse reactions included hypertension(385 cases), elevated blood pressure(291 cases), myocardial infarction(182 cases), hypotension(175 cases), and atrial fibrillation(142 cases). The adverse reaction signals were consistent with the excavation signals, although adverse reactions such as aortic rupture, aortic valve calcification, and atrial fibrillation were not listed in the drug instructions. Conclusion Drug evaluation should be performed before the clinical use of nintedanib, especially for high-risk patients with cardiovascular diseases such as vascular disease, ischemic heart disease,and arrhythmia. Monitoring using electrocardiogram, electrolyte measurement, cardiac ultrasound, and other techniques should be strengthened, and clinicians should pay attention to adverse reactions beyond those listed in the instructions are included to ensure the safe use of this drug.

Key words: Nintedanib, Adverse event reporting system, Real-world research, Data mining, Cardiovascular adverse reaction signals

CLC Number: 

  • R574
[1] Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis[J]. Lancet, 2017, 389(10082): 1941-1952.
[2] Onoue S, Yamada S. Pirfenidone in respirable powder form for the treatment of pulmonary fibrosis: a safer alternative to the current oral delivery system?[J]. Ther Deliv, 2013, 4(8): 887-889.
[3] Maher TM, Bendstrup E, Dron L, et al. Global incidence and prevalence of idiopathic pulmonary fibrosis[J]. Respir Res, 2021, 22(1): 197.
[4] Diamantopoulos A, Wright E, Vlahopoulou K, et al. The burden of illness of idiopathic pulmonary fibrosis: a comprehensive evidence review[J]. PharmacoEconomics, 2018, 36(7): 779-807.
[5] Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis(an update)and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline[J]. Am J Respir Crit Care Med, 2022, 205(9): e18-e47.
[6] Richeldi L, Varone F, Bergna M, et al. Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence[J]. Eur Respir Rev, 2018, 27(150): 180074.
[7] Vacchi C, Manfredi A, Comb GC, et al. Combination therapy with nintedanib and sarilumab for the management of rheumatoid arthritis related interstitial lung disease[J]. Case Rep Med, 2020,2020:6390749. doi: 10.1155/2020/6390749.
[8] Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease[J]. N Engl J Med, 2019, 380(26): 2518-2528.
[9] Wollin L, Maillet I, Quesniaux V, et al. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis[J]. J Pharmacol Exp Ther, 2014, 349(2): 209-220.
[10] Yannick A, Virginia DS, Masataka K, et al. Thu0330 Effects Of Nintedanib in patinets with systemic sclerosis-associated ILD(SSC-ILD)and differing extents of skin fibrosis: further analyses of the senscis trial[J]. Annals of the rheumatic diseases, 2020, 79(0003-4967):395-396.
[11] Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis[J]. N Engl J Med, 2014, 370(22): 2071-2082.
[12] Crestani B, Huggins JT, Kaye M, et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON[J]. Lancet Respir Med, 2019, 7(1): 60-68.
[13] 代菲, 陈盛新, 舒丽芯, 等. 5种信号挖掘方法在药物不良反应检测中的分析和应用[J].中国医院药学杂志, 2012, 32(20): 1674-1677.
[14] Goldman A, Maor E, Bomze D, et al. Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-Cell therapy[J]. J Am Coll Cardiol, 2021,78(18): 1800-1813.
[15] Noth I, Wijsenbeek M, Kolb M, et al. Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials[J]. Eur Respir J, 2019, 54(3): 1801797.
[16] Li L, Chen Y, Shi C. Nintedanib ameliorates oxidized low-density lipoprotein-induced inflammation and cellular senescence in vascular endothelial cells[J]. Bioengineered, 2022, 13(3): 6196-6207.
[17] Kondo M, Kisanuki M, Kokawa Y, et al. Case report: QT prolongation and abortive sudden death observed in an 85-year-old female patient with advanced lung cancer treated with tyrosine kinase inhibitor osimertinib[J]. Front Cardiovasc Med, 2021, 8: 655808.doi: 10.3389/fcvm.2021.655808.
[18] Choudhary A, Manouchehri A, Moslehi J, et al. Abstract 12978: identification of cardiovascular adverse effects associated with midostaurin- a WHO pharmacovigilance database analysis[J]. Circulation, 2020, 142: A12978. doi:10.1161/circ.142.supp1-3.12978.
[19] Patel RB, Ning H, de Boer IH, et al. Fibroblast growth factor 23 and long-term cardiac function: the multi-ethnic study of atherosclerosis[J]. Circ cardiovasc Imaging, 2020, 13(11): e011925.
[20] Liu Y, Li Y, Wang YX, et al. Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy[J]. Hematol Oncol, 2022, 15(1): 89.
[21] Pérez-Gutiérrez L, Ferrara N. Biology and therapeutic targeting of vascular endothelial growth factor A[J]. Nat Rev Mol Cell Biol, 2023, 24(11): 816-834.
[22] Taku T, Yasushi S, Takanori K, et al. Nintedanib-induced gastric antral vascular ectasia in patients with idiopathic pulmonary fibrosis[J]. ACG Case Reports Journal, 2023, 10(2326-3253): e01107.
[23] Lu AJ, Lai L, Ali H-JR, et al. Abstract 17047: nintedanib and cardiomyopathy: a vascular failure?[J] Circulation, 2021, 144: A17047. doi:10.1161/.circ.144: supp1-2-17047.
[24] Umbarkar P,Singh AP, Tousif S, et al. Repurposing Nintedanib for pathological cardiac remodeling and dysfunction[J]. Pharmacol Res, 2021, 169: 105605. doi:10.1016/j.phrs.2021.105605.
[25] 李宗阳, 敬赟鑫, 李彩霞, 等. 国外典型药物警戒数据库研究及经验借鉴[J].中国药物评价, 2021, 38(4): 265-273. LI Zongyang, JING Yunxin, LI Caixia, et al. Pharmacovigilance Evaluation of Zileuton Based on FAERS[J]. Chinese Journal of Drug Evaluation, 2021, 38(4): 265-273.
[1] LYU Mingyue, SUN Hanchen, LUO Qingxin, XU Zhaoke, XU Ruize, ZHANG Shuo, YAN Luning, HU Xifeng, ZHAO Qingbo, ZHU Gaopei, XUE Fuzhong. Therapeutic effect of nifedipine and metoprolol on heart disease [J]. Journal of Shandong University (Health Sciences), 2025, 63(9): 1-10.
[2] WU Yutong, WU Sijia, YANG Jianwei, HE Yina, LI Hongkai, HUANG Lin, LIU Yunxia. Association analysis of medical device adverse events in Shandong Province in 2021: Apriori algorithm [J]. Journal of Shandong University (Health Sciences), 2022, 60(12): 111-118.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd